A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors

Sponsor
Bristol-Myers Squibb
Study ID
NCT03792750
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Advanced Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986205 — DRUG
    Specified Dose on Specified Day
  • Nivolumab — BIOLOGICAL
    Specified Dose on Specified Day

Study Details

The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.

Key Dates

Start date
Dec 31, 2018
Status verified
Feb 2022
Primary completion
Dec 18, 2020
Completion
Dec 18, 2020

Study Design

Enrollment
12 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental Arm A
    2 week BMS-986205 monotherapy lead in followed by BMS-986205 + Nivo combination therapy

Primary Outcome Measure

The Number of Participants Experiencing Adverse Events (AE) [ Time Frame: From first dose to 100 days after last dose of study therapy (up to approximately 2 years) ]

Related Studies